Antimicrobial Discovery Platform Bridging Innovation and Access
First-in-class Antifungal Discovery and Development
What We Do
AI/ML led discovery of novel antifungal chemotypes, from hit identification through preclinical candidate selection and development
Why It Matters
Fungal disease burden keeps rising while few genuinely new mechanisms reach patients, and access in India lags global launches
Fungal infections
Global burden
6.5MLife-threatening fungal infections each year
2.5MDeaths attributed to fungal infection each year
19WHO priority fungal pathogens
Annual incidence (estimated cases, millions)
GlobalIndia
Invasive aspergillosis
Invasive candidiasis
Mucormycosis
Estimated annual cases in India
~200kInvasive Aspergillosis
~500kInvasive Candidiasis
~150kMucormycosis
At risk population
~1 in 100ICU patients
~10 in 100Leukaemia patients
~10 in 100Transplant recipients
Emergence of Antifungal Resistance
>50%Azole resistance
~30%C. auris multidrug resistant
~10%Echinocandin resistance
Sources: WHO 2022; GAFFI 2023; Denning 2024; Ray 2022; ISCCM 2024; Chakrabarti 2025; Prakash 2021; Prakash 2019